Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 14/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402788 | 0.84 | TBXAS1 (0.64) | TBXAS1ALDH1A1KDM4ELMNAEGLN3 | |
| SCHEMBL501807 | 0.84 | TBXAS1 (0.60) | TBXAS1ALDH1A1KDM4ELMNAEGLN3 | |
| SCHEMBL5859786 | 0.83 | TBXAS1 (0.55) | TBXAS1ALDH1A1KDM4ELMNAEGLN3 | |
| SCHEMBL501640 | 0.83 | TBXAS1 (0.54) | TBXAS1ALDH1A1KDM4ELMNAEGLN3 | |
| SCHEMBL4793009 | 0.83 | ALDH1A1 (0.47) | TBXAS1ALDH1A1EGLN3 | |
| SCHEMBL12304848 | 0.83 | TBXAS1 (0.52) | TBXAS1ALDH1A1KDM4ELMNAEGLN3 | |
| SCHEMBL10653577 | 0.82 | TBXAS1 (0.58) | TBXAS1LMNASMN1; SMN2 | |
| SCHEMBL9897520 | 0.82 | EGLN3 (0.67) | TBXAS1ALDH1A1LMNAEGLN3MEN1 | |
| Hydrochloric Acid SCHEMBL11828470 | 0.81 | TBXAS1 (0.56) | TBXAS1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24490919 | 0.81 | TBXAS1 (0.50) | TBXAS1ALDH1A1KDM4ELMNAEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11762287-B2 | Onium salt compound, chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-09-19 | — | — | US | disclosed |
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20220127225-A1 | ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| US-20210179554-A1 | ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-20200249571-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| CN-102875606-B | Copper diphosphonate complex and preparation method and application thereof | JIANGSU INST NUCLEAR MEDICINE | 2015-03-25 | — | — | CN | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| CN-102875606-A | Copper diphosphonate complex and preparation method and application thereof | JIANGSU INST NUCLEAR MEDICINE | 2013-01-16 | — | — | CN | disclosed |
| US-8101567-B2 | Heteroaryl-containing tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| CN-101786990-B | Compound having anti-itching activity | UNIV HEFEI TECHNOLOGY | 2012-01-18 | — | — | CN | disclosed |
| CN-101786990-A | Compound having anti-itching activity | UNIV HEFEI TECHNOLOGY | 2010-07-28 | — | — | CN | disclosed |
| US-7728148-B2 | Acyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7629108-B2 | Nitrogen-containing organic compound, resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20090202485-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080102405-A1 | Nitrogen-containing organic compound, resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200249571-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | PAG1, LIFR, GIGYF2 | TBXAS1 4662/4885ALDH1A1 1477/4885KDM4E 2171/4885 |
| US-20230205083-A1 | SALT COMPOUND, RESIST COMPOSITION AND PATTERNING PROCESS | SLC6A9, SLC6A5, REN | TBXAS1 4437/4885ALDH1A1 3949/4885KDM4E 3950/4885 |
| US-20080102405-A1 | Nitrogen-containing organic compound, resist composition and patterning process | MDM4, MUS81, NOP2 | TBXAS1 2649/4885ALDH1A1 4502/4885KDM4E 1401/4885 |
| US-20210179554-A1 | ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SLC6A5, LIFR, SLC6A9 | TBXAS1 4725/4885ALDH1A1 4242/4885KDM4E 4034/4885 |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | TBXAS1 1759/4885ALDH1A1 764/4885KDM4E 900/4885 |
| US-20220127225-A1 | ONIUM SALT, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | CACNA1F, SLC6A5, IDUA | TBXAS1 4802/4885ALDH1A1 3860/4885KDM4E 3328/4885 |
| US-11762287-B2 | Onium salt compound, chemically amplified resist composition and patterning process | IDUA, SLC6A5, SLC6A9 | TBXAS1 4636/4885ALDH1A1 4322/4885KDM4E 4195/4885 |
| US-20090202485-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | PRSS1, CTSC, SPINT2 | TBXAS1 3050/4885ALDH1A1 1657/4885KDM4E 2139/4885 |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | CTSC, PRSS1, SPINT2 | TBXAS1 3739/4885ALDH1A1 1805/4885KDM4E 2045/4885 |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | TBXAS1 1273/4885ALDH1A1 637/4885KDM4E 905/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | TBXAS1 1759/4885ALDH1A1 764/4885KDM4E 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.